The rapid advancements in digital therapeutics are placing Japan at the forefront of the digital health movement. This emerging field has significant implications for the global life sciences industry, making Japan a crucial player to watch.
One issue that is impacting access to essential services for justice-involved patients is the gap in Medicaid coverage. Patients who were formerly incarcerated often face challenges related to substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases. Addressing this gap is crucial for ensuring that these individuals receive the necessary care and support to improve their health outcomes.
Artificial Intelligence (AI) is increasingly being utilized in the workplace, with generative AI tools offering new opportunities for enhancing productivity. Understanding how to effectively harness the power of AI can help individuals and organizations stay ahead in today’s fast-paced business environment.
The US Food and Drug Administration (FDA) recently approved the subcutaneous administration of Takeda’s ENTYVIO (vedolizumab) for maintenance therapy in patients with moderately to severely active Crohn’s disease. This approval provides patients with an alternative treatment option, expanding access to this important medication for those in need.
Michael L. Kyle, M.D., highlighted the positive impact of a drug developed by Currax Pharmaceuticals LLC in an interview with George Hampton of Pharmaceutical Executive. The drug has shown significant efficacy in weight loss and obesity prevention, thanks to the dedicated team at Currax Pharmaceuticals LLC for their commitment to advancing healthcare and patient safety. To share news in Pharma Pulse, reach out to Social Media Editor Miranda Schmalfuhs.
